--- title: 'Senior Director, Payer Accounts at REGENXBIO' canonical: 'https://feeny.ai/job/senior-director-payer-accounts-regenxbio-remote-s2pgqn6da73z' type: 'job' last_seen: '2026-11-09' --- # Senior Director, Payer Accounts at REGENXBIO - **Company:** REGENXBIO - **Location:** Remote - **Employment:** full-time - **Work type:** remote - **Posted:** 2026-11-03 - **Last confirmed live:** 2026-11-09 - **Apply:** https://jobs.lever.co/regenxbio/e394eaba-c7e8-4ddb-97bb-8182eccf3b45 ## Job description Since our founding in 2009, REGENXBIO has pioneered what’s possible in gene therapy. Today, we are advancing a pipeline of gene therapies designed to improve the lives of patients facing serious rare and retinal diseases and preparing to bring innovative new medicines to patients. Our work is fueled by purpose and urgency because every day matters to patients and their families. At REGENXBIO, you’ll find meaningful opportunities to grow, collaborate, and contribute to the advancement of potentially transformative gene therapies. Together, our talented team is working to make a meaningful difference for patients and their families. What we do matters. The Opportunity The Senior Director, Payer Accounts will play a critical role in ensuring patient access to REGENXBIO’s gene therapy portfolio by leading strategic engagement with key national and regional payers, PBM, and GPO accounts. This role is accountable for developing, negotiating, and executing market access strategies that secure timely and sustainable reimbursement while building long-term, trusted partnerships with payer decision-makers. As a member of the Market Access organization, the Senior Director Payer Accounts will collaborate closely with Market Access, Trade, Commercial Enablement, Marketing, HEOR, and Legal teams to align account strategies with brand and access objectives. ## How You’ll Contribute - Build and oversee the national and payer account teams. - Develop and execute strategic account plans for national and regional payers, PBMs, specialty pharmacies, and IDNs to achieve optimal coverage and reimbursement for REGENXBIO’s therapies. - Serve as the primary point of contact and business owner for assigned payer accounts, ensuring alignment of objectives, proactive issue resolution, and consistent communication. - Establish and maintain senior-level relationships with key payer stakeholders (e.g., VP of Pharmacy, Medical Directors, Contracting Executives, Clinical Policy leads). - Lead contract strategy and negotiations, including value-based and innovative access models, aligned with corporate and brand goals. - Analyze payer policies, utilization trends, and competitive dynamics to identify opportunities and anticipate potential access barriers. - Monitor contract performance and compliance, providing actionable insights and recommendations to Market Access leadership. - Translate data-driven insights into strategic recommendations, leveraging internal analytics to communicate REGENXBIO’s differentiated value proposition. - Collaborate cross-functionally with Market Access, Trade, Commercial Enablement, Marketing, HEOR, and Sales to develop and execute pull-through initiatives supporting patient access. - Support the development of coverage education tools, reimbursement resources, AMCP dossier, PIE material and payer-facing value materials in collaboration with internal stakeholders. - Partner with Medical, Legal, and Compliance to ensure all payer engagements and materials adhere to regulatory and ethical standards. - Provide market intelligence to inform national access planning and support leadership decision-making. - Travel up to 50–60% of the time, including overnight travel, is required - It is imperative that REGENXBIO employees embody our core values by working collaboratively, building strong relationships and using clear communication to meet shared objectives. ## What You’ll Bring We are looking for someone who thrives in a collaborative, patient-focused environment with the following skills: - Bachelor’s degree required; advanced degree (MBA, MPH, or equivalent) preferred. - 12+ years of recent experience in the biopharmaceutical industry, including 5+ years in national or regional payer account management roles and 3+ years in leadership roles managing national or regional account teams. - Strong expertise in rare diseases and/or gene therapies, with a strong understanding of the U.S. payer landscape, including commercial payers, Medicare, Medicaid, integrated delivery networks, market access, and reimbursement. - Demonstrated success developing and executing payer strategies for high-cost specialty products especially for gene therapies and rare disease products. - Demonstrated success in contract negotiation, formulary access, and strategic account planning within specialty, Gene therapy, rare disease, or high-cost therapy categories. - Experience with value-based contracting, alternative reimbursement models, or innovative access solutions strongly preferred. - Strong business and clinical acumen with the ability to connect therapeutic value to payer priorities. - Proven ability to influence and engage senior stakeholders, both externally with payers and internally across functions. - Proven ability to navigate complex cross-functional environments and influence internal and external stakeholders. - Excellent presentation, analytical, and communication skills; adept at translating data into clear strategic insights. - Strong leadership, coaching, and communication skills with the ability to navigate complexity and ambiguity. - High integrity, adaptability, team-player and collaborative mindset, with a patient- focused approach and comfort working in a dynamic, small-company environment, aligned with REGENXBIO’s core values. - Ability to travel up to 50–60%, including overnight travel. ## What You Can Expect At REGENXBIO, we're committed to fostering an environment where people can do meaningful work, grow professionally, and make an impact. Our core values - trust, accountability, perseverance, and innovation - drive everything we do. We offer a comprehensive and competitive benefit and compensation package that includes market-competitive salaries, an annual bonus program, education assistance, paid caregiver leave, a retirement plan with employer match, stock options at all levels, summer hours, and more. The estimated compensation range for this role is $245,000 - $350,000 annually. The actual salary offered to the final candidate depends on factors such as relevant work experience, skills, education, and years of experience. ## About REGENXBIO ## Company Overview - **One-liner**: REGENXBIO is a clinical-stage biotechnology company developing one-time gene therapies for rare and retinal diseases using its proprietary AAV vector platform. - **Entity Type**: Public (NASDAQ: RGNX) - **Headquarters**: Rockville, Maryland, United States - **Founded**: 2008 (founded as a company; operations began in 2009) - **Founders**: Not publicly listed as individual founders; the company was spun out from the gene therapy research of the University of Pennsylvania and licensed its NAV Technology Platform from the university. ## Core Business - **Primary industry**: Biotechnology – Gene Therapy (AAV-based) - **Target customers**: B2B (pharma partners like AbbVie, Nippon Shinyaku) and B2G (regulatory agencies, clinical trial sites); ultimate customers are patients with rare and retinal diseases (Duchenne muscular dystrophy, MPS I, MPS II, wet AMD, diabetic retinopathy). - **Mission or purpose statement**: “To improve lives through the curative potential of gene therapy.” [regenxbio.com](https://www.regenxbio.com/culture-careers/) ## Products & Services - **NAV® Technology Platform**: Proprietary AAV vector gene delivery platform (including AAV8 and AAV9) used for internal programs and licensed to partners (e.g., Novartis for ZOLGENSMA®). - **ABBV-RGX-314** (in collaboration with AbbVie): Investigational one-time gene therapy for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR). In pivotal clinical trials. - **RGX-202** (Duchenne muscular dystrophy): Phase I/II/III AFFINITY DUCHENNE® trial; pivotal phase expected to support BLA submission in 2026 using accelerated approval pathway. [ir.regenxbio.com](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa) - **RGX-121** (MPS II – Hunter syndrome): In partnership with Nippon Shinyaku; late-stage development. - **RGX-111** (MPS I – Hurler syndrome): In partnership with Nippon Shinyaku; clinical development. - **Manufacturing**: In-house cGMP production facility (REGENXBIO Manufacturing Innovation Center – RMIC) in Rockville, MD, operational since mid-2022. ## Market Standing - **Valuation/Market Cap**: $447.8 million (as of recent data). [linkedin.com](https://linkedin.com/company/regenx) - **Key Metric**: Annual Revenue $170.4 million (primarily from license and collaboration revenue). [linkedin.com](https://linkedin.com/company/regenx) - **Notable Investors/Partners**: - AbbVie (collaboration for ABBV-RGX-314) - Nippon Shinyaku (partnerships for RGX-121 and RGX-111) - Novartis (licensee for ZOLGENSMA® using NAV vectors) - **Growth Signals**: - Headcount: 296 employees (+1.3% YoY). [linkedin.com](https://linkedin.com/company/regenx) - BLA submission for RGX-202 targeted for 2026. - RMIC facility operational since 2022, enabling scalable clinical and commercial manufacturing. - Scholarly output: 160 works, 7,337 citations, field-weighted citation impact of 2.6 (highly influential). [linkedin.com](https://linkedin.com/company/regenx) ## Competitive Advantages - **Proprietary NAV Technology Platform**: Exclusive rights to a large portfolio of AAV vectors (including AAV8 and AAV9), the foundation for multiple approved and investigational gene therapies. [ir.regenxbio.com](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa) - **End-to-end capabilities**: Integrated in-house R&D, preclinical development, clinical development, and cGMP manufacturing. - **Proven platform**: Thousands of patients have been treated with AAV vectors from the NAV platform (including via Novartis’ ZOLGENSMA®). - **Late-stage pipeline**: Multiple programs in pivotal or near-pivotal trials (RGX-202, ABBV-RGX-314) with clear regulatory pathways. ## Strategic Focus - **Near-term**: Advance RGX-202 toward BLA submission in 2026; continue pivotal trials for ABBV-RGX-314 in wet AMD and diabetic retinopathy. - **Long-term**: Expand pipeline in retinal, neuromuscular, and neurodegenerative diseases; leverage RMIC for commercial-scale manufacturing; deepen partnerships with AbbVie and Nippon Shinyaku. - **Platform expansion**: Ongoing research to expand NAV vector capabilities and develop new AAV-based therapies. ## Why Work Here - **Mission-driven culture**: “Patient-focused, driven by results, fosters collaboration.” Core values emphasize accountability, innovation, and serving patients with limited therapeutic options. [regenxbio.com](https://www.regenxbio.com/culture-careers/) - **Impactful work**: Opportunity to work on one-time gene therapies that could fundamentally alter the course of devastating diseases. - **Growth & stability**: Public company with late-stage pipeline, strong partnerships, and a clear path to commercialization. - **Location & facilities**: Headquarters in Rockville, MD, with a state-of-the-art cGMP manufacturing facility (RMIC) on site. - **Work policy**: Not explicitly stated as remote/hybrid; positions appear to be on-site (based on job listings in Rockville and field-based Medical Science Liaison roles). - **Perks**: Comprehensive and competitive benefits for employees and families. [regenxbio.com](https://www.regenxbio.com/culture-careers/) - **Engineering & science culture**: High scholarly output and citation impact; emphasis on cross-functional collaboration between research, manufacturing, and clinical teams. - **Recruitment note**: REGENXBIO warns of fraudulent job offers; all applications go through their official Lever portal. [regenxbio.com](https://www.regenxbio.com/culture-careers/) ## Sources 1. [regenxbio.com – Culture & Careers](https://www.regenxbio.com/culture-careers/) 2. [linkedin.com – REGENXBIO company page](https://linkedin.com/company/regenx) 3. [ir.regenxbio.com – 10-K Filing (Business Overview)](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa) 4. [ir.regenxbio.com – Investor Overview](https://ir.regenxbio.com/investor-overview) 5. [jobs.lever.co – REGENXBIO careers](https://jobs.lever.co/regenxbio) ## Other roles at REGENXBIO - [Market Development Director - Northeast Region](https://feeny.ai/job/market-development-director-northeast-region-regenxbio-northeast-united-states-p1aq4vpnf89y) — Northeast United States - [Market Development Director - Central Region](https://feeny.ai/job/market-development-director-central-region-regenxbio-central-united-states-15nj813awggq) — Central United States - [Market Development Director - West Region](https://feeny.ai/job/market-development-director-west-region-regenxbio-west-coast-1j7btq7v405v) — West Coast - [Accounts Payable Coordinator](https://feeny.ai/job/accounts-payable-coordinator-regenxbio-maryland-m7bjbn7g5wje) — Maryland - [Lead Integration Developer](https://feeny.ai/job/lead-integration-developer-regenxbio-rockville-x52a6y2n5b0w) — Rockville, MD - [VP, Global Rare Disease Franchise](https://feeny.ai/job/vp-global-rare-disease-franchise-regenxbio-remote-zw2996mdrwy4) - [Vice President, Information Technology](https://feeny.ai/job/vice-president-information-technology-regenxbio-rockville-ekqdx4dtve6s) — Rockville, MD - [People Intern](https://feeny.ai/job/people-intern-regenxbio-rockville-mq2tm3vcjxe7) — Rockville, MD - [Associate Director, Regulatory Affairs](https://feeny.ai/job/associate-director-regulatory-affairs-regenxbio-rockville-1grfyr3vz4sy) — Rockville, MD - [Head of Sales, Rare Disease](https://feeny.ai/job/head-of-sales-rare-disease-regenxbio-remote-qhp7fgpvfvzm)